openPR Logo
Press release

Phynexus, Inc. Enters Into An Agreement To Be Acquired By Biotage AB

12-05-2018 09:32 AM CET | Health & Medicine

Press release from: PhyNexus

PhyNexus

PhyNexus

San Jose, California, December 4, 2018 — PhyNexus, Inc., a privately held California corporation, announces today an agreement to be acquired by Biotage AB (Nasdaq Stockholm: BIOT.ST), strengthening its position for world-wide sales and marketing of automated lab-scale purification technology of biomolecules. Together, PhyNexus and Biotage will be able to provide their global customers an enabling automation platform based on Dual Flow Chromatography and patented tip technology for high throughput purification of biomolecules such as proteins, plasmids and antibodies at the lab-scale.

The companies will fully address the growing multi-billion USD market, including purification and manipulation of biomolecules. PhyNexus and Biotage believe that the combination of technology and resources will also enable the development of new approaches for clinical, forensic, food and environmental testing.

PhyNexus technology enables miniaturized and parallel automated work-flows to address different laboratory purification processes. The company’s Dual Flow Chromatography tip technology has the ability to draw up samples, process them and re-deposit them into sample wells. The processed samples are ready for use or, if desired, may be processed with additional tips to bring the sample to the desired form in a completely automated work-flow. The platform technology delivers high throughput purification capability with improved results across multiple applications in biologics drug discovery, research and development, and diagnostic applications.

Torben Jörgensen, CEO of Biotage, comments: "The acquisition of PhyNexus is in line with our strategy to grow our separation business through expansion into new application areas. This transaction enables PhyNexus’ products to reach a larger global market through Biotage’s direct sales organization, at the same time as Biotage obtains access to customers in industries where Biotage historically has not been as active. The acquisition is complementary to our existing offering and enables us to better address the growing biomolecules market. We are very much looking forward to accelerate our efforts in this fast emerging area.”

Douglas Gjerde, founder and CEO of PhyNexus, comments: “We are excited to partner with Biotage for the next phase of PhyNexus’ development. This combination will allow PhyNexus’ product offering to expand its footprint globally and open up new opportunities for developing and bringing new innovative products to the market."

About PhyNexus
San Jose, California-based PhyNexus offers protein and plasmid sample preparation columns and robotics. PhyNexus products miniaturize and automate purification while retaining the native state of the protein and/or provide transient transfection quality plasmids. The columns are modified to be compatible with all of the major robotic liquid handlers and with their own PhyNexus liquid handlers. PhyNexus customers are life scientists in pharmaceutical companies and academia doing research for drug target and validation, drug screening and lead optimization, drug development, clinical trials, and drug manufacturing.

About Biotage
Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm.

PhyNexus, Inc.
3670 Charter Park Dr., Ste A
San Jose, CA 95136
https://www.phynexus.com

Contacts:
Douglas Gjerde, CEO
Tel. +1 408 267 7214 x307,
Tiffany Nguyen, President
Tel. +1 408 267 7214 x305,

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Phynexus, Inc. Enters Into An Agreement To Be Acquired By Biotage AB here

News-ID: 1417236 • Views:

More Releases for Biotage

Peptide Synthesizer Market Insights, Segments, Future Growth and Strategies Anal …
Peptide synthesizers make an offering of the ability to synthesize and build complex peptides in a short period of time from the level of research to the level of production. In addition to that, advanced peptide synthesizers are able to synthesize multiple peptides at the same time. The changing landscape of the industry of healthcare with more emphasis on the development of novel therapeutics for the disorders and diseases are
Global Peptide Synthesizer Market - Biotage, Shimadzu, Activotec, CS Bio
Apex Research, recently published a detailed market research study focused on the "Peptide Synthesizer Market" across the global, regional and country level. The report provides 360° analysis of "Peptide Synthesizer Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Peptide Synthesizer industry, and estimates the future trend of Peptide Synthesizer market on
Biotage Launches ACI™ - Accelerated Chromatographic Isolation
Uppsala, Sweden (July 10, 2014) -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of ACI™ (Accelerated Chromatographic Isolation), a new advance converting simple flash purification into a faster and more economical way to isolate pure compounds. Biotage believes that ACI™ will radically improve the efficiency of the laboratory, embracing the latest developments in purification technology to guide chemists
Biotage Unveils New Fully Automated Microwave Peptide Synthesizer
Uppsala, Sweden, September 25, 2012 -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced an innovative new synthesis platform for peptide researchers at the 2012 European Peptide Symposium in Athens, Greece. The Biotage® Initiator+ Alstra is a fully automated, single channel, programmable microwave peptide synthesizer and is the latest addition to Biotage's growing family of peptide synthesis platforms. The Initiator+ Alstra
Biotage Moving Into Mass Directed Flash
Uppsala, Sweden, September 25, 2012 -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces that Biotage is in late stage development with its partner Microsaic Systems plc of a fully integrated solution for Mass Directed Flash with Biotage's flagship flash purification system Isolera™. A presentation will be held at the JASIS meeting in Makuhari, Japan on 5th September, 2012. The
Biotage Introduces SNAP Ultra High Performance Flash Chromatography Cartridges w …
Uppsala, Sweden, February 14, 2012 -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. Biotage® SNAP Ultra is available in a wide range of sizes from 10 g - 340 g. Biotage® HP-Sphere™ is chromatographically tested proprietary silica with 40% more surface area than previously available flash